Latest moves, page 4
- KRYS Down 11% New
Krystal Biotech falls 11% as pipeline delays overshadow a beat
Krystal Biotech beat profit estimates and approved a $400 million buyback, but pushed several pipeline milestones into 2027.
- LITE Down 18.6% New
Lumentum falls 19% as Marvell's slide cuts its takeover value
Marvell agreed to buy Lumentum for 4.5 Marvell shares each. Marvell's slide cut the offer's value, and Lumentum fell 19% to trade further below it.
-
Palantir Q3 2026: revenue up 96% and guidance raised again, but contract signings slow
Palantir beat its own Q3 revenue guide by about $150 million and raised its 2026 outlook, while new contract value grew 6% after 49% in Q2.
- IDXX Up 21.8% New
IDEXX jumps 22% on a beat and raise despite fewer vet visits
IDEXX beat third-quarter forecasts and raised its 2026 outlook as U.S. vet visits kept falling, after its stock had dropped 28% from its record close.
-
Midterms and stocks: what 80 years of history say, and what markets are pricing now
The S&P 500 rose in the 12 months after all 20 midterm elections since 1946. Here is what that history can and can't tell investors before Nov 3.
-
Reddit falls 55% since July after warnings of weaker search traffic
Reddit's sales keep growing fast, but it says Google is sending it fewer visitors and warned that its daily users could fall in the fourth quarter.
-
Corning falls 52% since June despite major AI fiber deals
Corning more than doubled on AI fiber deals with Nvidia and Amazon, then lost half its value from its June peak as results kept beating and spending rose.
- AGIO Down 17.9% New
Agios falls 18% as FDA delays sickle cell decision over safety review
Agios fell about 18% after the FDA pushed its decision on mitapivat for sickle cell disease to Feb 1, 2027, while it weighs whether a safety program is needed.
- CACC Down 19.3% New
Credit Acceptance falls 19% as it cuts its loan cash-flow forecast
Credit Acceptance's adjusted earnings topped estimates, but it cut its forecast of loan net cash flows by $291 million, producing a loss under standard accounting.
- BLOGNew
How our valuation model works: from company filings to a range of outcomes
A plain-English tour of our valuation model: what goes in, what comes out, how one quarter is simulated, and how we check the results.
- ILMN Down 18.6% UPDATED OCT 31New
Illumina falls 19% even as it raises its full-year forecast
Illumina shares fell after earnings despite a forecast raise. Tariff-related customer credits complicate the reported revenue miss.
-
Coinbase Q3 2026: revenue flat at $1.2 billion as costs fall and a crypto gain lifts profit
Coinbase's Q3 revenue held at $1.22 billion as trading stayed weak; costs came in below its range, and a gain on its own crypto supplied most of its profit.
-
Alnylam Q3 2026: shares fall 25%; US demand adds less revenue than in Q2
Alnylam shares fell 25% on Oct 29 after Q3 showed less added US demand revenue, higher costs and two delayed data updates.
- IOVA Down 35.4% New
Iovance falls 35% after lung cancer update highlights a small subgroup
Iovance called its lung cancer results positive, then the numbers showed most responses came from a small group of patients identified after the fact.
- NOW Down 27% New
ServiceNow falls 27% after forecasting slower contracted-revenue growth
ServiceNow beat its own targets, but forecast slower growth in contracted revenue after its stock had risen about 81% from its April 10 close.
- FTNT Down 20.1% New
Fortinet falls 20% after a beat as service growth slows
Fortinet beat forecasts and raised its revenue outlook, but cut its forecast for service revenue (subscriptions and support) while product sales did the heavy lifting.
- GOOGL Down 12.6% New
Alphabet falls 13% as cash burn and a profit miss overshadow a cloud boom
Alphabet fell about 13% on Thursday as investors weighed an ad-sales miss, negative free cash flow and a SpaceX paper loss against rapid Cloud growth.
-
Viking: our view and what our model says about 2030
Our analysis of Viking Therapeutics: what its obesity drug must deliver, the cash to get there, and what 50,000 simulations say about its end-2030 value.
-
Viking Therapeutics Q3 2026: trials on track, spending up 44% and nearly $1 billion in cash
Viking's Q3 research expense rose 44% from Q2, and September financing lifted cash and short-term investments to $960 million. Its Phase 3 timelines held.
-
Nvidia: our view and what our model says about 2030
Our analysis of Nvidia: growth backed to fiscal 2028, the new risk of customer financing, and what 50,000 simulations say about its value at the end of 2030.